Functional validation experiments confirmed the crucial role of ICOSL in mediating DC–T cell interactions under tumor-conditioned conditions, highlighting the potential of targeting the ICOS–ICOSL axis as a therapeutic strategy in CCA. This evidence concerns the gene ICOS and cholangiocarcinoma.